Skip to main content

Table 2 Disease characteristics & treatment

From: Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA

  

UK*

France

Spain

Italy

Germany

USA

Total

Last time the women experienced the symptoms

N

 

107

100

105

106

102

520

Today

N (%)

 

5 (4.7%)

4 (4.0%)

7 (6.7%)

7 (6.6%)

7 (6.9%)

30 (5.8%)

Less than a week ago

N (%)

 

27 (25.2%)

18 (18.0%)

20 (19.1%)

20 (18.9%)

22 (21.6%)

107 (20.6%)

1 to 4 weeks ago

N (%)

 

42 (39.3%)

49 (49.0%)

55 (52.4%)

42 (39.6%)

47 (46.1%)

235 (45.2%)

1 to 3 months ago

N (%)

 

24 (22.4%)

24 (24.0%)

15 (14.3%)

23 (21.7%)

24 (23.5%)

110 (21.2%)

3 to 6 months ago

N (%)

 

6 (5.6%)

4 (4.0%)

5 (4.8%)

10 (9.4%)

2 (2.0%)

27 (5.2%)

More than 6 months ago

N (%)

 

3 (2.8%)

1 (1.0%)

3 (2.9%)

4 (3.8%)

0

11 (2.1%)

Symptoms today: n (%)

N

 

5

4

7

7

7

30

Vaginal itching and/or Burning

N (%)

 

5 (100.0%)

4 (100.0%)

7 (100.0%)

6 (85.7%)

4 (57.1%)

26 (86.7%)

Thick, white or yellowish vaginal discharge

N (%)

 

4 (80.0%)

4 (100.0%)

6 (85.7%)

4 (57.1%)

5 (71.4%)

23 (76.7%)

Pain on intercourse

N (%)

 

2 (40.0%)

3 (75.0%)

2 (28.6%)

1 (14.3%)

3 (42.9%)

11 (36.7%)

Pain and burning on urination

N (%)

 

0

1 (25.0%)

4 (57.1%)

3 (42.9%)

4 (57.1%)

12 (40.0%)

Number of infections

        
 

N

100

107

100

105

106

102

620

 

Mean (SD)

5.74 (2.19)

5.22 (1.43)

5.22 (1.45)

5.28 (1.54)

5.05 (1.26)

5.60 (1.81)

5.34 (1.64)

Duration of infection (days)

        
 

N

100

107

100

105

106

102

620

 

Mean (SD)

6.96 (5.00)

7.01 (4.31)

10.75 (12.25)

7.43 (4.94)

6.50 (4.76)

6.66 (4.65)

7.57 (6.77)

Patients treatment with long-term antifungal therapy

N

100

107

100

105

106

102

620

Patients never treated

N (%)

68 (68.00%)

45 (42.06%)

45 (42.45%)

29 (27.62%)

72 (69.23%)

64 (62.75%)

321 (51.8%)

Patients currently treated

N (%)

12 (12.00%)

29 (27.10%)

25 (23.81%)

42 (40.38%)

9 (8.49%)

26 (25.49%)

141 (22.7%)

Previously treated

N (%)

20 (20.00%)

33 (30.84%)

36 (33.96%)

34 (32.38%)

23 (22.11%)

12 (15.79%)

158 (25.5%)

  1. *Data about symptoms not available for the UK, as questions about symptoms were formulated differently in the UK version.
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us